​Gedeon Richter Plc. (“Richter”) today announced that it has entered into a license agreement with Mochida Pharmaceutical Co. Ltd. (“Mochida”) in respect of Richter’s biosimilar tocilizumab (“Product”) for the treatment of rheumatoid arthritis.

According to the agreement Mochida receives rights to develop, manufacture and commercialise the Product in Japan. Under the terms of the agreement Mochida shall disburse milestone payments in a number of instalments pending on development and regulatory stages completed.

"We are looking forward to a close co-operation with Mochida as a promising step to expand the global reach of our biosimilar portfolio in the therapeutic field of rheumatology," – said Gábor Orbán, Chief Executive Officer of Richter.


About tocilizumab

Tocilizumab is a biological product used in the treatment of rheumatoid arthritis. The product is also approved for the treatment of paediatric juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, giant cell arteritis and CAR-T cell-induced cytokine release syndrome. It is available in both subcutaneous and intravenous formulations.


About Richter

Gedeon Richter Plc. (www.richter.hu), headquartered in Budapest/Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe, in China and in Latin America. Having reached a market capitalization of EUR 3.6 billion (USD 4.1 billion) by the end of 2019, Richter's consolidated sales were approximately EUR 1.6 billion (USD 1.7 billion) during the same year. The product portfolio of Richter covers many important therapeutic areas, including Women's Healthcare, Central Nervous System and Cardiovascular areas. Having the largest R&D unit in Central Eastern Europe, Richter's original research activity focuses on CNS disorders. With its widely acknowledged steroid chemistry expertise, Richter is a significant player in the Women's Healthcare field worldwide. Richter is also active in biosimilar product development.



For more information:


Katalin Ördög:                                    +36 1 431 5680



Zsuzsa Beke:                                     +36 1 431 4888